Documents

Displaying 1 - 20 of 83 results
 
Collapse Filters
 
Expand Filters         +
October 28, 2019

Fentanyl Signature Profiling Program Report

The Fentanyl Signature Profiling Program (FSPP) performs in-depth chemical analyses on fentanyl and fentanyl-related exhibits obtained from seizures made throughout the United States.  This report details the results and conclusions derived from these analyses that are reported on a quarterly basis. FSPP data is not intended to reflect U.S. market share, but is rather a snapshot of samples submitted to this laboratory from the 7 DEA regional laboratories.

October 25, 2019

Prevenir El Uso De Marihuana Entre Adolescentes Y Adultos Jóvenes

Prevenir El Uso De Marihuana Entre Adolescentes Y Adultos Jóvenes (Preventing Marijuana use in Youth and Young Adults) 

October 23, 2019

Analysis of Drugs Manual

This document is an internal Drug Enforcement Administration quality system document.  The document is updated periodically and current as of October 23, 2019 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

October 18, 2019

Fentanyl in Chicago – By the Numbers

The Drug Enforcement Administration (DEA) Chicago Field Division (CFD) conducted a study of all exhibits containing fentanyl and/or fentanyl-related substances (FRS) acquired within the CFD’s area of responsibility (AOR) between fiscal year (FY) 2015 and FY 2019 up to May 30, 2019. The CFD AOR includes the States of Illinois, Indiana, and Wisconsin. The exhibits included those acquired by DEA and other federal agencies, such as the Bureau of Alcohol, Tobacco, Firearms and Explosives and the Federal Bureau of Investigation.

October 11, 2019

Vaping and Marijuana Concentrates: What is Vaping?

Vaping is the act of inhaling and exhaling an aerosol or vapor made from a liquid or dry material that is heated in an electronic powered device, called an electronic cigarette, or e-cigarette.  In addition to nicotine and flavored liquids, marijuana concentrates can also be vaped. This 6-panel, double-sided trifold brochure covers the effects of using e-cigarettes, as well as the effects of marijuana concentrate

September 19, 2019

Drug Caused Deaths in the LA Field Division

The phenomenon of drug overdose death has grown steadily worse in the United States during most of the 21st century and has been skyrocketing since 2013 and the introduction of illicitly manufactured fentanyl-related substances into the domestic drug market...

September 16, 2019

Drug-Related Overdose Deaths in Pennsylvania, 2018 (BUL-132-19)

Since 2014, the Drug Enforcement Administration (DEA) Philadelphia Division Intelligence Program (PDIP) has annually collected and analyzed data and disseminated perceived trends and key findings that concern drug-related overdose deaths in Pennsylvania. This analysis has informed a multi-disciplinary audience relating to the drugs, populations, and geographic areas of greatest concern...

May 31, 2019

Updating the Prescription Opioid Threat in Pennsylvania

The Drug Enforcement Administration (DEA) Philadelphia Division’s Intelligence Program (PDIP) reviewed a set of data indicators for the years 2015-2018 to assess the current prescription opioid threat in Pennsylvania. Analysis revealed that a positive change in the prescription opioid threat may be underway...

April 25, 2019

SFL8 Summary of Validated Methods

This document is an internal Drug Enforcement Administration quality system document which provides a summary of validated qualitative and quantitative methods from the Southwest Laboratory (SFL8).  The document is updated periodically and current as of April 25, 2019 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

April 25, 2019

SFL7 Summary of Validated Methods

This document is an internal Drug Enforcement Administration quality system document which provides a summary of validated qualitative and quantitative methods from the Western Laboratory (SFL7).  The document is updated periodically and current as of April 25, 2019 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

April 25, 2019

SFL6 Summary of Validated Methods

This document is an internal Drug Enforcement Administration quality system document which provides a summary of validated qualitative and quantitative methods from the South Central Laboratory (SFL6).  The document is updated periodically and current as of April 25, 2019 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

April 25, 2019

SFL5 Summary of Validated Methods

This document is an internal Drug Enforcement Administration quality system document which provides a summary of validated qualitative and quantitative methods from the North Central Laboratory (SFL5).  The document is updated periodically and current as of April 25, 2019 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

April 25, 2019

SFL4 Summary of Validated Methods

This document is an internal Drug Enforcement Administration quality system document which provides a summary of validated qualitative and quantitative methods from the Southeast Laboratory (SFL4).  The document is updated periodically and current as of April 25, 2019 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

April 25, 2019

SFL3 Summary of Validated Methods

This document is an internal Drug Enforcement Administration quality system document which provides a summary of validated qualitative and quantitative methods from the Mid-Atlantic Laboratory (SFL3).  The document is updated periodically and current as of April 25, 2019 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

April 25, 2019

SFL2 Summary of Validated Methods

This document is an internal Drug Enforcement Administration quality system document which provides a summary of validated qualitative and quantitative methods from the Northeast Laboratory (SFL2).  The document is updated periodically and current as of April 25, 2019 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

 

April 25, 2019

SFL1 Summary of Validated Methods

This document is an internal Drug Enforcement Administration quality system document which provides a summary of validated qualitative and quantitative methods from the Special Testing and Research Laboratory (SFL1).  The document is updated periodically and current as of April 25, 2019 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

 

April 25, 2019

Summary of Validated Methods

This document is an internal Drug Enforcement Administration quality system document which provides a summary of validated quantitative methods.  The document is updated periodically and current as of April 25, 2019 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

February 19, 2019

Athletes and Opioids Poster

What is prescription pain reliever misuse? As defined by the National Survey on Drug Use and Health, it’s “use without a prescription of one’s own or use at a higher dosage or more often than prescribed.” Prescription opioid addiction – stemming from misuse – has hit the nation hard in recent years. Unfortunately, high school student-athletes can be especially vulnerable to prescription painkiller misuse. This poster encourages teens, parents and other caregivers, and educators to know the risks around misusing pain pills.

October 29, 2018

Heroin Domestic Monitor Report

The DEA Heroin Domestic Monitor Program (HDMP) is a retail-level heroin purchase program that provides data analysis about the geographic source of heroin along with price, purity, adulterants, and diluents sold at the street-level in 27 U.S. cities. The data in this report is from 2016.

DEA US Badge
United States Drug Enforcement Administration DEA.gov is an official site of the U.S. Department of Justice